Roma and Marvin Auerback Distinguished Professor of Pediatric Molecular Oncology, UCSF
Member, UCSF Biomedical Sciences Graduate Program (BMS)
Co-Leader, Hematopoietic Malignancies Program, UCSF Helen Diller Family Comprehensive Cancer Center
| CONTACT | |
|
(415) 476-3831 (appts) Box 0519, UCSF; San Francisco, CA 94143-0519 |
additional websites: |
| EDUCATION | |
|
Williams College, Williamstown, MA, A.B., 1976, Biology, Liberal Arts
|
|
| PROFESSIONAL EXPERIENCE | |
|
1982-85 |
Attending Pediatrician, Naval Hospital, Oakland, CA |
|
1985-88 |
Fellow in Pediatric Hematology/Oncology and Instructor in Pediatrics, UCSF |
|
1988-92 |
Attending Pediatric Hematologist/Oncologist, Naval Hospital, Oakland, CA |
|
1992-94 |
Assistant Professor of Pediatrics and Attending Pediatric Hematologist/Oncologist, UCSF |
|
1989-93 |
Hematopoietic Growth Factors Subcommittee, American Society of Hematology |
|
1990-present |
Acute Myelogenous Leukemia Strategy Group Children's Cancer Study Group (Co-Chair 1997-99) |
|
1988-93 |
Cancer Biology Committee, Children's Cancer Study Group (Chair 1991-94) |
|
1991-92 |
Pediatric Residency Program Director, Naval Hospital, Oakland, CA |
|
1994-98 |
Associate Professor of Pediatrics, UCSF |
|
1997-present |
Leader, Program in Hematopoietic Malignancies, UCSF Cancer Center |
|
1997-present |
Professor of Pediatrics, UCSF |
|
2005 |
Vice Chair for Research, Department of Pediatrics, UCSF |
|
2006 |
Director, UCSF Medical Scientist Training Program |
| HONORS & AWARDS | |
|
1985 and 1989 |
Outstanding Teacher, Pediatrics Department, Naval Hospital, Oakland |
|
1985 and 1993 |
Navy Commendation Medals |
|
1986 |
Outstanding Fellow's Teaching Award, Pediatrics Department, UCSF |
|
1988 |
David W. Smith Research Award, Western Society for Pediatric Research |
|
1988 and 1989 |
Navy Achievement Medals |
|
1992 |
Winner, Navy Academic Medicine Research Competition |
|
1993 |
Nycomed Research Award of the International Society for Pediatric Oncology (SIOP) |
|
1994 |
Ross Outstanding Young Investigator Award, Western Society for Pediatric Research |
|
1998 |
American Academy of Pediatrics Award for Excellence in Pediatric Research |
|
2000 |
Roma and Marvin Auerback Distinguished Professor of Pediatric Molecular Oncology, UCSF |
|
2004 |
Samuel Rosenthal Prize for Excellence in Academic Pediatrics |
|
2006 |
National Cancer Institute MERIT Award |
| SELECTED PUBLICATIONS | |
|
(selected from 83 research articles and 50 reviews/chapters) | |
|
Emerling BM, Bonifas J, Kratz CP, Green ED, Le Beau MM, Shannon KM. Cloning and characterization of M7LDS1, a Drosophila trithorax homolog located in a segment of chromosome band 7q22 implicated in myeloid leukemia. Oncogene 2002; 21: 4849-4854. | |
|
Shannon KM. Resistance in the land of molecular cancer therapeutics. Cancer Cell 2002; 2: 99-102. | |
|
Donovan S, See W, Bonifas J, Stokoe D, Shannon KM. Hyperactivation of protein kinase B and ERK have discrete effects on survival, proliferation, and cytokine expression in Nf1-deficient myeloid cells. Cancer Cell 2002: 2: 507-514. | |
|
Downing JR, Shannon KM. Acute leukemia: a pediatric perspective. Cancer Cell 2002: 2: 437-445. | |
|
Aiyagari A, Taylor B, Aurora V, Young SG, Shannnon KM. Hematologic effects of inactivating the Ras processing enzyme Rce1. Blood 2003; 101: 2250-2252. | |
|
Ingram DJ, Wenning MJ, Shannon K, Clapp DW. Leukemic potential of doubly mutant Nf1 and Wv hematopoietic cells. Blood 2003; 101: 1984-1986. | |
|
Wong S, McLaughlin J, Cheng D, Shannon K, Robb L, Witte ON. IL-3 receptor signaling is dispensable for BCR-ABL-induced myeloproliferative disease. Proc Natl Acad Sci USA 2003; 100: 11630-11635. | |
|
Loh ML, Vattikuti S, Reynolds MG, Carlson EJ, Schubbert S, Lieuw KH, Cheng JW, Stokoe D, Bonifas JM, Curtiss NP, Gotlib J, Meshinchi S, Le Beau MM, Emanuel PD, Shannon KM. Somatic mutations in PTPN11 implicate the protein tyrosine phosphatase SHP-2 in leukemogenesis. Blood 2004; 103: 2325-2331. | |
|
Braun BS, Tuveson DA, Kong N, Le DT, Kogan SC, Rozmus J, Le Beau MM, Jacks TE, Shannon KM. Somatic activation of oncogenic Kras in hematopoietic cells induces a fatal myeloproliferative disorder. Proc Natl Acad Sci USA 2004; 101: 597-602. | |
|
Side LE, Curtiss NP, Teel K, Kratz C, Wang PW, Larson RW, Le Beau MM, Shannon KM. RAS, FLT3, and TP53 Mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7. Genes Chromosomes Cancer 2004; 39: 217-223. | |
|
Le DT, Kong N, Zhu Y, Lauchle JO, Aiyigari A, Braun BS, Wang E, Kogan SC, Le Beau MM, Parada L, Shannon KM. Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder. Blood 2004; 103: 4243-4250. | |
|
Braun BS, Shannon KM. The sum is greater than the FGFR1 partner. Cancer Cell 2004; 5: 203-204. | |
|
Van Etten RA, Shannon KM. Focus on myeloproliferative diseases and myelodysplastic syndromes. Cancer Cell 2004; 6: 547-552. | |
|
Schubbert S, Lieuw K, Rowe SL, Lee CM, Li XX, Loh ML, Clapp DW, Shannon KM. Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells. Blood 2005; 106: 311-17. | |
|
Curtiss NP, Bonifas JM, Lauchle JO, Balkman JD, Kratz CP, Emerling BM, Green ED, Le Beau MM, Shannon KM. Isolation and analysis of candidate myeloid tumor suppressor genes from a commonly deleted segment of 7q22. Genomics 2005; 85: 600-607 | |
|
Katsumoto TR, Duda J, Kim A, Wardak Z, Dranoff G, Clapp DW, Shannon K. Granulocyte-macrophage colony stimulating factor signaling and donor accessory cells modulate radioprotection by purified hematopoietic cells. J Exp Med 2005; 201: 853-858. | |
|
Shannon KM, Van Etten RA. JAKing up hematopoietic proliferation. Cancer Cell 2005; 7: 291-93. | |
|
Chao RC, Pyzel U, Fridlyand J, Kuo, Y-M, Teel L, Haaga J, Borowsky A, Horvai A, Kogan SC, Bonifas J, Huey B, Jacks TE, Albertson D, Shannon K. Therapy-induced malignant neoplasms in Nf1 mutant mice. Cancer Cell 2005; 8: 337-48. | |
|
Lauchle, JO, Braun BS, Loh ML, Shannon KM. Inherited predispositions and hyperactive Ras in myeloid leukemogenesis. Pediatric Blood and Cancer 2006; 46: 579-586. | |
|
Schubbert S, Zenker M, Rowe SL, Bšll S, Klein C, Bollag G, van der Burgt I, Musante L, Wehner L-E, Nguyen H, West B, Rauch A, Niemeyer CM, Shannon K*, Kratz CP. Germline KRAS mutations cause Noonan syndrome. Nat Genet 2006; 38: 331-38 (* - Corresponding Author). | |
|
Stephens K, Weaver M, Leppig K, Maruyama K, Emanuel PD, Davis EM, Espinosa R, Le Beau MM, Shannon KM. Tumor suppressor inactivation by double mitotic recombination at clustered breakpoint intervals. Blood 2006; 108: 1684-9. | |
|
Braun BS, Archard J, Van Ziffle JA, Tuveson DA, Jacks TE, Shannon K. Somatic activation of a conditional KrasG12D allele causes ineffective erythropoiesis in vivo. Blood 2006; 108: 2041-44. | |
|
Gutmann DH, Hunter-Schaedle K, Shannon KM. Harnessing preclinical mouse models to inform human clinical cancer trials J Clin Invest 2006; 116: 847-852. |
|
|
1/22/07 |
|
